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Summary
Background: Treatment of rheumatic or musculoskeletal disor-
ders (MD) is multi-disciplinary and includes herbal analgesics. 
Although already reviewed, no quantitative evaluation of effi-
cacy and safety of the herbal combination Phytodolor® (STW1) 
is available. Methods: We searched in databases and contacted 
authors and the manufacturer to identify randomized controlled 
trials (RCTs) examining STW1 in patients with MD. We made a 
re-analysis of raw data of eligible published and unpublished 
RCTs and pooled the results for meta-analysis according to 
 Cochrane guidelines and intention-to-treat. Primary outcome 
measure was patient global assessment of efficacy, secondary 
outcome measure was pain at rest and on movement. Results 
were stratified according to treatment groups. Results: Patient 
data of 11 RCTs were eligible for pooling. In the entire popu-
lation, STW1 was significantly superior compared to placebo in 
patients’ global assessment of efficacy (group difference for 
rating very good/good: 20%; placebo 48.9% and STW1 69.1%; 
p < 0.001; OR 0.43; 95% CI 0.28–0.65) and in the subpopu- 
 lation ‘other rheumatic diseases’ (placebo 45.4%; STW1 72.3%; 
p < 0.001; OR 0.32; 95% CI 0.2–0.52), but not in the subpopula-
tion ‘gonarthrosis’. STW1 did not differ significantly compared 
to non-steroidal anti-inflammatory drugs (NSAIDs), neither in 
the entire population nor the subpopulations. Similar results 
were found for pain at rest and on movement. No serious ad-
verse events (AE) but minor AE were reported (placebo 8.1%; 
STW1 14.2%; NSAIDs 18.9%). Conclusion: According to the an-
alysed data, STW1 showed a better pain reduction than pla-
cebo in patients with pain due to MD, probably equivalent to 
NSAIDs, and was well tolerated.
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Zusammenfassung
Hintergrund: Rheumatische bzw. muskuloskeletale Erkrankun-
gen werden multidisziplinär, einschließlich pflanzlicher Analge-
tika, behandelt. Obwohl das pflanzliche Kombinationspräparat 
Phytodolor® (STW1) in Übersichtsarbeiten behandelt wurde, 
liegt keine quantitative Analyse zur Wirksamkeit und Sicherheit 
vor. Methoden: Wir durchsuchten Datenbanken und kontaktier-
ten Autoren sowie den Hersteller, um randomisierte kontrol-
lierte Studien (RCTs) über STW1 bei Patienten mit muskuloske-
letalen Erkrankungen zu finden. Wir führten eine Reanalyse der 
Rohdaten der geeigneten publizierten und unpublizierten RCTs 
durch und «poolten» die Ergebnisse für eine Meta-Analyse 
nach den Cochrane-Richtlinien und «Intention-to-treat». Der pri-
märe Zielparameter war die globale Patientenbewertung der 
Wirksamkeit, der sekundäre war Schmerz in Ruhe und Bewe-
gung. Die Ergebnisse wurden nach Behandlungsgruppen strati-
fiziert. Ergebnisse: Patientendaten aus 11 RCTs waren zur 
 Poolbildung geeignet. STW1 war dem Placebo bezüglich der 
globalen Bewertung der Wirksamkeit durch die Patienten so-
wohl in der Gesamtpopulation (Gruppendifferenz der Anteile 
mit Bewertung sehr gut/gut 20%; Placebo 48,9% und STW1 
69,1%; p < 0,001; OR 0,43; 95% CI 0,28–0,65) als auch in der 
 Untergruppe «andere rheumatische Erkrankungen» (Placebo 
45,4%; STW1 72,3%; p < 0,001; OR 0,32; 95% CI 0,2–0,52) signifi-
kant überlegen, aber nicht in der Untergruppe «Gonarthrose». 
STW1 unterschied sich nicht signifikant im Vergleich zu nicht-
steroidalen Antirheumatika (NSARs), weder in der Gesamtpo-
pulation noch in den Subpopulationen. Ähnliche Ergebnisse 
fanden sich bei den Parametern Schmerz in Ruhe oder Bewe-
gung. Es traten keine schwerwiegenden unerwünschten Ereig-
nisse auf; nur geringfügige unerwünschte Ereignisse wurden 
berichtet (8,1% der Patienten mit Placebo; 14,2% STW1; 18,9% 
NSAR). Schlussfolgerung: Entsprechend der analysierten Daten 
ist STW1 bei Patienten mit rheumatisch bedingten Schmerzen 
analgetisch wirksamer als Placebo, etwa vergleichbar zu NSAR, 
und wird gut vertragen.
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 research – even as a primary outcome [24, 25]. In order to per-
form a rigorous meta-analysis we decided to re-analyse the 
raw data according to the current standard and to examine 
whether treatment responses might differ in specific indica-
tions (subgroups), e.g. ‘gonarthritis’.
Methods
Search Strategy
For this meta-analysis the following databases were retrieved, each from 
its start till September 2009: AMED, Embase, Cochrane Collaboration, 
TOXLINE, MEDLINE and HealthSTAR. Search terms were: muscu-
loskeletal disorders, osteoarthritis, pain, Phytodolor®, rheumatic, STW1. 
Additionally, reference lists from pertinent articles and books were scru-
tinised, and experts in the field and the manufacturer were contacted.
Selection Criteria
Inclusion criteria for the studies of this meta-analysis were double- or 
single-blind randomized controlled trials (RCTs) with adequate statistical 
reporting like intention-to-treat (ITT) analysis or available raw data 
 allowing such an analysis. Studies that did not meet these criteria were 
excluded. Paucity of the published data led to the inclusion of unpub-
lished studies to compensate publication bias. The primary objective of 
the review is to assess efficacy and safety of STW1, taking into account 
clinically relevant endpoints. Due to the great number of unpublished 
RCTs we decided not to use the Jadad score [26] which was coined to 
 increase internal validity of trial reporting. The guidelines provided by 
the Cochrane Collaboration Handbook for Reviews [27] have been ap-
plied in the analysis of the clinical data.
Study Parameters
In the examined studies, patients with various MDs, e.g. back pain, epi-
condilitis, spondilitis, rheumatic arthritis or gonarthritis, were treated. 
The primary endpoint parameter was patient global assessment of effi-
cacy on a 4-point Likert scale (rating: unchanged, moderate, good, very 
good) because it was uniformly used across the trials in contrast to func-
tional indices like the Schober or Lequesne Index, which had been used 
only in a few trials. The available secondary endpoints were pain at rest 
and pain on movement (rating of severity: severe, moderate, mild, ab-
sent) and proportion of patients free of the symptom. In 1 RCT [28], pain 
was measured by visual analogue scale (VAS), whereas the values have 
been transformed (VAS: 0 = absent; below median at admission = mild; 
above median at admission = moderate/severe) and have shown compara-
ble validity in this approach [29]. Ratings were available at baseline, day 
7, 14 and last visit (mean: 21 days; range: 7–28 days).
Statistics
All included studies were analysed following current standards, pooled 
and reported as ITT and last observation carried forward (LOCF). To 
ensure that the meta-analysis of the published and unpublished data was 
based on a reliable and comparable ground, all raw data from the in-
cluded RCTs were re-analysed. As a consequence, the findings are not 
necessarily identical to those given in prior publications.
For stratification trials were allocated into two groups: ‘placebo-’ or 
‘NSAID-controlled’ (i.e. pooling diclofenac with other NSAIDs). Since a 
large proportion of the trials dealt with gonarthrosis, we also allocated 
trials into two subgroups: ‘predominantly gonarthrosis’ (including ‘pure’ 
gonarthrosis in [28]) and ‘predominantly other rheumatic disorders’ (in-
cluding some patients with gonarthrosis in [28]).
The studies were tabulated and appropriate software [30] was used for 
the validation of results. The data were summarised in tables and statisti-
cally analysed: In case of dichotomous data, odds ratio (OR) and rate dif-
Introduction
Musculoskeletal or rheumatic disorders are a major cause of 
morbidity throughout the world (e.g. osteoarthritis of the 
knee in 40% of the people over 70) and have a substantial 
 influence on health, quality of life and cost for health systems 
[1, 2]. Rheumatic diseases are usually associated with pain and 
loss of function. Due to their mostly degenerative and chronic 
character, a multimodal long-term therapy with pharmaco-
logical and non-pharmacological approaches with several 
steps in care is required to meet the patients’ needs [3, 4]. 
There is some evidence for the efficacy of herbal drugs, such 
as topical application of capsaicin [4–7] or oral treatment with 
extracts from Harpagophytum procumbens [8, 9] for pain re-
duction in osteoarthritis (OA). Yet, not all herbal prepara-
tions available today have been analysed in detail. One of 
those is STW1, known as Phytodolor®, produced by Steiger-
wald GmbH, Darmstadt, Germany. 100 ml of the standard-
ised herbal combination contain 60 ml of fresh bark and 
leaves of Populus tremula (drug extract ratio (DER) 4.5:1), 
20 ml of fresh bark of Fraxinus excelsior (DER 4.5:1) and 
20 ml of fresh Solidago virgaurea (DER 4.8:1); each a 60 
vol.-% ethanolic extract. The recommended dose in patients 
with musculoskeletal disorders (MDs) is usually 20 to 30 
drops (40 in severe cases), 3–4 times daily.
In preclinical studies, STW1 has shown several modes of 
action including the inhibition of cyclooxygenate-1 and -2 
(COX-1, COX-2), lipoxygenate (LOX), cytokines, elastase/
hyaluronidase [9, 10] and protection of oxidative damage [11]. 
In rodents, analgesic and anti-inflammatory activities have 
been shown at doses of 5–10 mg/kg [12].
However, clinical evidence of STW1 seems somewhat in-
consistent although reviewed in the literature [6, 9, 13, 14]. 
Conclusions from systematic reviews range from ‘potential 
(effective) in alleviating pain’ [15] or ‘suggested reduced pain’ 
[16] or ‘moderate support for pain’ [7] to ‘significant pain re-
duction’ [6]. So far, no meta-analysis has been published to 
assess the quantitative efficacy of STW1 in patients with MDs, 
although a meta-analysis was announced in 2007 [13]. A re-
cent review states that a meta-analysis based on the available 
published trials [9, 14] is all but impossible.
However, STW1 is widely used and one of the leading 
herbal medicinal combination products in Germany for mus-
culoskeletal complaints, probably because patients prefer 
herbal medicine as they expect less side-effects compared to 
non-steroidal anti-inflammatory drugs (NSAIDs) and other 
analgesics [17, 18].
In this situation, we assumed it to be crucial to evaluate 
 efficacy and safety of STW1 in patients with painful MDs. It 
was our aim to include published and unpublished studies and 
to concentrate on patient global assessment as primary out-
come, which is suitable in respect of the subjective impair-
ment of patients due to chronic pain. It is widely discussed in 
general [19–21] as well as in pharmacological [22–24] pain 
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Primary Outcome – Patient Global Assessment of Efficacy in 
NSAID-Controlled Studies 
In the entire patient population, STW1 was not significantly 
different from NSAIDs (group difference for rating good/very 
good: –0.1%, NSAIDs 52.9%, STW1 52.8%; table 3). In the 
sensitivity analysis, the outcome was not driven by any partic-
ular trial.
In the subpopulation ‘other rheumatic diseases’, no signifi-
cant difference was seen (group difference for rating good/
very good: 9.9%, NSAIDs 57.7%, STW1 67.7%; OR 0.65; 
95% CI 0.39 to 1.09; fig. 1). In the sensitivity analysis, the out-
come favoured NSAIDs significantly (p < 0.05) after eliminat-
ing the corresponding patients from the trial [38].
In the subpopulation ‘gonarthrosis’, no significant differ-
ence was noticed (group difference for rating good/very good: 
–3.1%, NSAIDs 50.4%, STW1 47.4%; OR 1.13; 95% CI 0.81 
to 1.57; fig. 2).
ference according to Peto Mantel-Haenszel [30] were used; ordinal data 
were analysed with the 2Trend [31] or an equivalent method. In case of con-
tinuous data, pooling as weighted mean difference and inverse variance 
were used. Where appropriate, the number needed to treat (NNT) was 
given. Sensitivity analyses were performed in the event of significant 
 results. Significance was calculated using two-sided tests, the threshold 
of significance being p ≤ 0.05.
For safety analysis only, all studies reporting any safety data (inci-
dence of adverse events (AE)) were included. Most studies reported 
spontaneous AE.
Results
The research strategy revealed only 1 trial with STW1 in the 
electronic databases [32]. 13 publications and 28 additional 
clinical study reports were identified through other channels 
(42 published and unpublished trials with 3,095 patients: 9 
placebo-controlled trials with 205 patients; 12 NSAID-con-
trolled trials with 469 patients and 2 trials of untreated pa-
tients with 20 patients). Yet, 30 studies had to be excluded 
because they were non-comparative or incomplete (e.g. no 
raw data available, no study report). 12 trials (4 published 
[32–35], 8 unpublished [28, 36–42]) were retained fulfilling the 
inclusion criteria (STW1: 680 patients; placebo: 200 patients; 
NSAIDs: 383 patients; table 1). One had to be excluded 
 because of significant differences between groups at baseline 
(Ritchie index [37]). 11 RCTs were included in the meta- 
analysis for efficacy and their raw data could be re-analysed. 
Female patients slightly outnumbered males by a proportion 
of 5 to 4 in all treatment groups; age was comparable in the 
STW1 (57.0 ± 10.2 years) and placebo group (57.3 ± 10.1 
years), but in the NSAIDs group patients were older (61.9 ± 
10.4 years; p < 0.001).
Outcomes
Primary Outcome – Patient Global Assessment of Efficacy in 
Placebo-Controlled Studies
In the entire patient population, STW1 was significantly supe-
rior to placebo (group difference for rating good/very good: 
20.3%, placebo 48.9% and STW1 69.1%; p < 0.001; OR 0.43; 
95% CI 0.28 to 0.65; NNT 4.9; table 2). In the sensitivity 
 analysis, significance was not driven by any particular trial, 
 although it dropped to p < 0.05 after elimination of one of 
the studies [43].
In the subpopulation ‘other rheumatic diseases’, STW1 
was significantly superior to placebo as well (group difference 
for rating good/very good: 26.9%, placebo 45.4%, STW1 
72.3%; p < 0.001; OR 0.32; 95% CI 0.2 to 0.52; NNT 3.7; table 
2), although it included a small subpopulation of patients with 
gonarthrosis [28]. In the sensitivity analysis, significance was 
not driven by any particular trial, too. In the subpopulation 
with gonarthrosis, no difference was seen in STW1 and 
placebo.
Table 2. Patient global assessment in placebo-controlled studies
Parameters All points Other rheumatic OA knee
STW1
 Very good 34.0% 35.8% 27.5%
 Good 35.1% 36.5% 30.0%
 Moderate 22.3% 20.9% 27.5%
 Poor  8.5%  6.8% 15.0%
 Number 188 148 40
Placebo
 Very good 17.8% 17.0% 20.5%
 Good 31.1% 28.4% 41.0%
 Moderate 26.7% 27.0% 25.6%
 Poor 24.4% 27.7% 12.8%
 Number 180 141 39
 P-value <0.001 <0.001 N.S.
N.S. = Not significant; OA = osteoarthritis.
Table 3. Patient global assessment in NSAID-controlled studies
Parameters All points Other rheumatic OA knee
STW1
 Very good 20.0% 30.8% 16.1%
 Good 32.8% 36.8% 31.3%
 Moderate 27.7% 21.1% 30.2%
 Poor 19.4% 11.3% 22.4%
 Number 494 133 361
NSAIDs
 Very good 24.5% 24.4% 24.6%
 Good 28.4% 33.3% 25.8%
 Moderate 27.0% 31.7% 24.6%
 Poor 20.1% 10.6% 25.0%
 Number 359 123 236
 P-value N.S. N.S. N.S.
N.S. = Not significant; OA = osteoarthritis.
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compound. In the subpopulation ‘gonarthrosis’, NSAIDs 
(n = 206) were significantly superior to STW1 (n = 319) at last 
visit (10% more pain-free patients with NSAIDs; p = 0.006). 
The outcome in this subpopulation was not driven by any 
 particular trial and was similar when restricted to diclofenac 
as reference compound.
Secondary Outcome – Pain on Movement in Placebo- 
Controlled Studies
In the entire patient population (table 1), pain on movement 
was significantly more reduced with STW1 (n = 136) com-
pared to placebo (n = 136) after 2 weeks (pain rating: mild/
absent; STW1 74.3%; placebo 59.6%; p = 0.005) and consoli-
dated at last visit (STW1 79.5%; placebo 62.3%; p < 0.001). 
The results were similar in the subpopulation ‘other rheu-
matic diseases’ (STW1 90.9%; placebo 67.2%), but showed no 
difference in patients with ‘gonarthrosis’ (STW1 45.0%; pla-
cebo 47.5%). In the sensitivity analysis, the outcome was not 
driven by any particular trial, neither in the entire population 
nor in any of the subpopulations. It is interesting to note that 
more patients became pain-free at rest than on movement, 
 independent of the treatment.
Secondary Outcome – Pain on Movement in NSAID- 
Controlled Studies
No difference in the reduction of pain on movement in STW1 
(n = 495) and NSAIDs (n = 351) could be seen, neither in the 
entire patient population (table 1) nor the subpopulations at 
any time during the treatment. In the sensitivity analysis, the 
outcomes were not driven by any particular trial.
Secondary Outcome – Pain at Rest in Placebo-Controlled 
Studies 
In the entire patient population in the studies that reported 
on this variable (table 1) for STW1 (n = 141), pain at rest was 
significantly reduced compared to placebo (n = 143) after 
2 weeks of treatment (pain rating: mild/absent; STW1 84.4%; 
placebo 63.6%; p = 0.003). Yet, this was less evident at last 
visit (STW1 81.3%; placebo 72.9%; p = 0.046). In the sensitiv-
ity analysis, the outcome was not driven by any particular 
trial, although the difference became significant after exclu-
sion of trials mainly dealing with ‘gonarthrosis’. In the sub-
population ‘other rheumatic diseases’ (n = 252), the difference 
between treatments was significantly in favour of verum after 
14 days (STW1 88.8%; placebo 61.3%) and at last visit (STW1 
91.3%; placebo 77.8%; p = 0.014). The high placebo response 
rate might be explained by the fact that patients additionally 
had access to rescue medications and other treatments. In the 
subpopulation ‘gonarthrosis’, no difference between treat-
ments could be detected at last visit; however, the number of 
patients was relatively small (n = 40 in each group).
Secondary Outcome – Pain at Rest in NSAID-Controlled 
Studies
In the entire patient population (table 1), pain reduction was 
progressive in both treatments, with no significant differences 
in STW1 (n = 469) and NSAIDs (n = 340). Similar results 
were observed in the subpopulation ‘other rheumatic dis-
eases’ (4.8% more pain-free patients with STW1). In the sen-
sitivity analysis, the outcome was not driven by any particular 
trial and was similar when restricted to diclofenac as reference 
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Fig. 1. Plot showing the pooled data of the rate difference between 
STW1 and NSAIDs in % of patients assessing efficacy ‘good/very good’ 
in the subpopulation ‘other rheumatic diseases’ (mean and 95% CI). Pos-
itive differences are in favour of STW1.
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Fig. 2. Plot showing the pooled data of the rate difference between 
STW1 and NSAIDs in % of patients favouring the rating efficacy ‘good/
very good’ in the subpopulation ‘gonarthrosis’ (mean and 95% CI). Posi-
tive differences are in favour of STW1.
254 Forsch Komplementmed 2011;18:249–256 Uehleke/Brignoli/Rostock/Saller/Melzer
suffering from chronic pain [21]. Global assessments are used 
in RCTs in OA [24] or rheumatic arthritis [20] as well as in 
meta-analyses [22]. Furthermore, patient global assessments 
provided a common global primary outcome parameter in 
mixed study populations with MDs, such as OA of hip, knee, 
shoulder, elbow, hands and spinal disorders, while different 
functional indices would be difficult to compare. Due to strat-
ification of disease groups, the limitations of the treatment 
with STW1 for OA of the knee became clear as well.
The strength of this meta-analysis is the re-analysis of raw 
data of each RCT according to current standards and ITT. 
Nevertheless, there are several limitations such as the single-
blind design in studies of STW1 versus reference drugs as well 
as very short wash-out periods before starting the trials and 
the short-term intervention in most of the studies. The use of 
rescue medication and non-pharmacological therapies, which 
is not unusual in trials with patients suffering from chronic 
pain, might have contributed to the reduction of any potential 
difference in treatments.
The main findings of this meta-analysis show that the treat-
ment with STW1 is associated with a good patient global as-
sessment of efficacy, significantly versus placebo; with a signifi-
cant pain reduction compared to placebo in patients with MDs, 
but without OA of the knee. The comparison of STW1 and 
NSAIDs revealed no significant difference of assessments of 
efficacy in treatments. Pain reduction was rather comparable in 
MDs, but again not in the OA of the knee. No conclusions can 
be drawn regarding rheumatoid arthritis. The results of the 
meta-analysis suggest that there may be different response 
 patterns for articular pain, as seen in gonarthrosis, and other 
generalized forms of pain, as seen in other MDs, e.g. back pain. 
This might be an explanation for the delayed onset of the 
herbal medicinal product, which is no problem in stable chronic 
conditions, but possibly in inflammatory exacerbatings.
Safety
In the examined studies no serious AE were reported (table 4). 
Among the spontaneously reported non-serious AE the hier-
archy of incidence was: placebo < STW1 < NSAIDs (signifi-
cantly more frequent in the STW1 than in the placebo group; 
p = 0.03; less frequent in the STW1 than in the NSAIDs group; 
p = 0.048). The most common AE with both STW1 (12.0%) 
and NSAIDs (15.7%) were gastrointestinal disorders (e.g. epi-
gastric symptoms), followed by unspecified symptoms such as 
headache, vertigo and skin disorders (e.g. exanthema). How-
ever, AE induced only a few patients to withdraw from the tri-
als (STW1 4.4%; NSAIDs 3.1%; placebo 1.5%). Nevertheless, 
it is noteworthy that about two-thirds of the non-serious AE 
with STW1 (14.2%) were reported in one trial [39]. Yet, the 
authors gave no explanation for this observation. Overall, the 
frequencies of AE and withdrawals were similar to those 
 observed in a large survey conducted on 1,800 patients (15.6% 
reported spontaneously AE; 3.2% withdrawals) [44].
Discussion
Patient global assessment of efficacy is used as primary out-
come for this meta-analysis, since it was available and also 
used in pharmacological [22–24] pain research (as primary 
outcome [24, 25]) and it seems suitable to provide a fair idea 
of the clinical short-term efficacy of STW1 in patients suffer-
ing from limi tations due to pain from MDs. While functional 
indices or  biomarkers have been used as outcome measures in 
MD  patients, global assessments seem to be able to measure 
pain intensity as well as the patients’ broader perception of 
the  disease. Therefore, it may provide an accurate and sensi-
tive assessment of the multiple subjective aspects in patients 
Parameters STW1 NSAIDs Placebo
number % number % number %
Patients 660 100.0 381 100.0 198 100.0
Serious AE 0   0 0   0.0 0   0.0
AE 94  14.2 72  18.9 16   8.1
Withdrawal due to AE 29   4.4 12   3.1 3   1.5
Body as a whole 16   2.4 20   5.2 4   2.0
Nervous system disorders 1   0.2 0   0.0 0   0.0
Respiratory, thoracic,  
mediastinal disorders
0   0 1   0.3 1   0.5
Gastrointestinal disorders 79  12 60  15.7 7   3.5
Hepato-biliary disorders 1   0.2 1   0.3 0   0.0
Skin and subcutaneous  
tissue disorders
4   0.6 8   2.1 5   2.5
Renal and urinary disorders 1   0.2 0   0.0 0   0.0
Injury and poisoning 1   0.2 0   0.0 0   0.0
Not specified 23   3.5 5   1.3 0   0.0
Table 4. AE from patients with reporting; 
classified according to body system (multiple 
mentions possible)
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search with the examined herbal medicinal product: a) RCTs 
should be sufficiently powered, b) the dosage should even-
tually be higher and c) long-term treatment needs to be 
evaluated.
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The finding that results of STW1 are better in the placebo-
controlled trials, compared to the NSAID-controlled trials, 
cannot be explained – one might speculate about an unblind-
ing effect.
The tolerance of STW1 in the examined trials shows low 
rates of spontaneous reporting of AE and is estimated fairly 
good and somewhat between placebo and NSAIDs.
Conclusions
The presented results for safety and efficacy are encouraging 
concerning patients global assessment of efficacy and pain 
 reduction in MD but not in OA of the knee. Additionally, 
this meta-analysis provided information to guide future re-
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